Etentamig Meets Both CERVINO Endpoints
AbbVie’s investigational BCMAxCD3 bispecific etentamig met both dual primary endpoints in the 393-patient Phase III CERVINO trial. Objective response was 74.0% versus 45.7% with investigator-selected standard therapy, and progression-free survival favored etentamig with a…
